This is a primary data collection-based special drug-use surveillance to be conducted in accordance with the GPSP ordinance.~Observational period will last 24 months from the start of treatment with Kesimpta.
This study is an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.